SCHEMBL3017499

SCHEMBL3017499

CCCc1ccc(Cc2csc(N3CCN(S(=O)(=O)c4ccc(Cl)cc4Cl)CC3)n2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV4 Q9HBA0 1/20 0.43
KDM2B Q8NHM5 1/20 0.41
HSD11B1 P28845 1/20 0.40
LPAR1 Q92633 1/20 0.40
LPAR2 Q9HBW0 1/20 0.40
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
LMNA P02545 3/20 0.39
MAPK1 P28482 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
POLB P06746 1/20 0.38
KDM4E B2RXH2 1/20 0.37
GAA P10253 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C19 P33261 1/20 0.37
MAPT P10636 3/20 0.36
THRB P10828 1/20 0.36
AR P10275 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3008787 0.93 MAPT (0.44) KDM2BNPC1RAB9ALMNAMAPK1
SCHEMBL3015465 0.92 TRPV4 (0.45) TRPV4KDM2BHSD11B1LPAR1LPAR2
SCHEMBL3021382 0.92 TRPV4 (0.48) TRPV4KDM2BHSD11B1LPAR1LPAR2
SCHEMBL2999916 0.91 ALDH1A1 (0.42) HSD11B1LMNAMAPK1MEN1KMT2A
SCHEMBL3008650 0.91 MEN1 (0.37) TRPV4HSD11B1LPAR1LPAR2LMNA
SCHEMBL3013342 0.90 TRPV4 (0.45) TRPV4KDM2BHSD11B1LPAR1LPAR2
SCHEMBL3015045 0.89 MEN1 (0.44) KDM2BLMNAMAPK1MEN1KMT2A
SCHEMBL3017691 0.88 CYP3A4 (0.52) RAB9ALMNAMAPK1MEN1KMT2A
SCHEMBL3018014 0.88 TRPV4 (0.57) TRPV4KDM2BHSD11B1LPAR1LPAR2
SCHEMBL3001076 0.88 TDP1 (0.46) TRPV4KDM2BHSD11B1LPAR1LPAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA TRPV4 2844/4885KDM2B 4152/4885HSD11B1 1034/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.